Granite (NYSE:GVA) is pleased to announce a Granite Inliner project, the Stamford Interceptor Trunk Sanitary Sewer Phase 1 Project for the Region of Niagara, Ontario, has been awarded the Association of Municipalities of Ontario (AMO) Gas Tax Award. The AMO Gas Tax Award recognizes excellence in the use of federal Gas Funds. The Niagara Region was presented this award for their investment of federal Gas Tax funding in an innovative sewer rehabilitation project in the City of Niagara Falls.
The Stamford Interceptor Trunk Sanitary Sewer Phase 1 Project was completed by LiquiForce, Granite Inliner’s Canadian-based rehabilitation services company, using a no-dig trenchless pipeline rehabilitation technology, also known as cured-in-place pipe (CIPP) lining. CIPP extends the life of hydraulically adequate sewers at lower cost than excavating and replacing sewers in the streets and is less disruptive to vehicular and pedestrian traffic during construction while minimizing the environmental impact.
LiquiForce rehabilitated 7,600 feet (2,300 meters) of new and existing 42-inch (1,050-millimeter) and 48-inch (1,200-millimeter) diameter sanitary sewer main and 23 manholes bypassing the entire system including three pumping stations.
The Honorable Catherine McKenna, Canada’s Minister of Infrastructure and Communities, addressed the Federal Gas Tax Awards ceremony, praising Niagara Region’s "very impressive work.”
"Congratulations to this year’s winner, Niagara Region,” said Minister McKenna. "You combined innovation and environmentally-friendly engineering and supported long-term planning with your sewer pipeline project. And you did a great job keeping the impact on the busy Niagara Falls tourism sector minimal.”
"It’s great to get recognition for the innovation that went into this project,” said Niagara Region Regional Chair, Jim Bradley. "The federal Gas Tax Fund played a very big role in making this happen.”
Read the AMO Gas Tax Award press release.
Granite is America’s Infrastructure Company™. Incorporated since 1922, Granite (NYSE:GVA) is one of the largest diversified construction and construction materials companies in the United States as well as a full-suite provider in the transportation, water infrastructure and mineral exploration markets. Granite’s Code of Conduct and strong Core Values guide the Company and its employees to uphold the highest ethical standards. In addition to being one of the World’s Most Ethical Companies for ten consecutive years, Granite is an industry leader in safety and an award-winning firm in quality and sustainability. For more information, visit graniteconstruction.com, and connect with Granite on LinkedIn, Twitter, Facebook and Instagram.
About Granite Inliner
Granite Inliner is one of the nation’s largest cured-in-place pipe and trenchless pipe providers, and offers sustainable pipeline rehabilitation services to both public and private sectors. Granite Inliner installs safe, cost-effective, and long-term solutions for aging water, wastewater and sewer infrastructure needs. In June 2018, they became a wholly-owned subsidiary of Granite Construction Incorporated.
LiquiForce is a leader in no-dig trenchless pipeline rehabilitation services for water and wastewater pipeline systems, and have offices in both Canada and the United States. Services include complete pipeline system inspection, assessment, rehabilitation and maintenance. In June 2018, LiquiForce became a wholly-owned subsidiary of Granite Construction Incorporated.
About Liner Products
Supplying more than 40 million feet of cured-in-place pipe (CIPP) liner since 1999, Liner Products has a strong legacy of being a trusted source and top supplier of high-performance pipe lining tubes and material throughout North America. In June 2018, Liner Products became a wholly-owned subsidiary of Granite Construction, Inc.
AMO is a non-profit organization representing almost all of Ontario’s 444 municipal governments. AMO supports and enhances strong and effective municipal government in Ontario and promotes the value of municipal government as a vital and essential component of Ontario and Canada’s political system.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005689/en/
Shares of Beyond Meat (NYSE: BYND) crashed this week after the company reported worse-than-anticipated sales on Monday. Fundamental analysis: “Shockingly weak” numbers Beyond Meat posted a sharp loss for the quarter due to a decline in demand for the company’s plant-based meat at restaurants and stores. The company reported a loss of $0.28 a share excluding items, compared to consensus estimates of a $0.05 profit. Credit Suisse analyst Robert Moskow described the latest results as “shockingly weak”. Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today. Net sales climbed by 2.7% to $94.4 million (£71.83 million), far away from consensus estimates of $132.81 million. Beyond Meat stock was also pressured by news that McDonald’s latest decision to roll out a new product called “McPlant”, which is also a line of plant-based meat. McDonald’s decision to launch its own plant-based burger comes after the end of its partnership with Beyond Meat, which many think is the main reason behind McDonald’s move. However, Ethan Brown, CEO of Beyond Meat thinks that was “greatly exaggerated”. “Our relationship with McDonald’s is good. It’s really strong. Our work there on behalf of what they’re doing continues,” he said.
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product LUMEVOQ® to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation in the ND4 mitochondrial gene.
"This first regulatory submission for GenSight is a major milestone in our progression from a pure research organization to one with commercial capabilities. It validates a technology platform that has the potential to address the high unmet medical needs of patients suffering from a range of rare diseases. I would like to thank all GenSight employees and partners whose motivation, focus and effort made this submission possible,” said Bernard Gilly, Co-founder and Chief Executive Officer of GenSight Biologics.
LHON is a rare, mitochondrial genetic disease, mainly affecting young males. The ND4 mutation results in the worst visual outcomes, with most patients becoming legally blind. There continues to be a high unmet medical need for the 800-1200 new LHON patients in Europe and the U.S. each year, particularly those who are struck blind in their prime working years.
Lenadogene nolparvovec (tradename: LUMEVOQ®) is a recombinant adeno-associated viral vector, serotype 2 (rAAV2/2), containing a cDNA encoding the human wild-type mitochondrial NADH dehydrogenase 4 protein (ND4), which has been specifically developed for the treatment of LHON associated with mutation in the ND4 gene. It received orphan drug designation status for the treatment of LHON from the EMA in 2011 and from the U.S. Food and Drug Administration (FDA) in 2013.
GenSight submitted the MAA based on the benefit-risk balance established by results from a Phase-I/IIa study (CLIN-01), two pivotal Phase-III efficacy studies (CLIN-03A: RESCUE, and CLIN-03B: REVERSE) and the long-term follow up study of RESCUE and REVERSE (CLIN 06 - readout at Year 3 post injection). To demonstrate the efficacy of LUMEVOQ® in the context of a contralateral effect, the Company used a statistics-based indirect comparison methodology to assess the visual outcomes in LUMEVOQ®-treated patients (from LUMEVOQ® efficacy studies) against those in untreated patients from Natural History studies and GenSight’s REALITY Natural History Registry.
GenSight expects to submit the Biologics License Application (BLA) for LUMEVOQ® to the FDA in H2 2021. First-in-human data from GenSight’s second clinical stage program, GS030, are expected to be available in H2 2021.
About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to the eye by intravitreal injection to offer patients a sustainable functional visual recovery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005857/en/